A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab.
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2013
At a glance
- Drugs Denosumab (Primary)
- Indications Metabolic bone diseases; Postmenopausal osteoporosis
- Focus Pharmacodynamics
- Sponsors Amgen
- 10 Jun 2017 Biomarkers information updated
- 16 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jun 2010 Planned end date changed from 1 Mar 2010 to 1 Aug 2010 as reported by ClinicalTrials.gov.